Study ID,Study,Experiment Name,Experiment Notes,Strain Ont ID,Strain,Sex,Age,# of Animals,Sample Notes,Clinical Measurement Ont ID,Phenotype,Formula,Clinical Measurement Notes,Average Type,Value,Units,SEM,SD,Method Ont ID,Method,Method Site,Method Duration,Method Notes,Post Insult Type,Post Insult Time Value,Post Insult Time Unit,Conditions,Record ID, 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",CD4-positive T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002345,blood CD45RC(high) CD4 T cell count to CD45RC(low) CD4 T cell count ratio,,,,0.08,%,0.008,0.03,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84690,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood insulin amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,84 days,25,,CMO:0000358,serum insulin level,,ng/ml is unit,,0.00005,mg/dl,0.0,0.0,MMO:0000075,enzyme linked immunosorbent assay,opthalmic venous plexus,0.0,,,,,control condition,70100,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood triglyceride amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,male,84 days,15,,CMO:0000360,serum triglyceride level,,,,159.2928,mg/dl,9.8253,38.0533,MMO:0000179,automated blood analysis,opthalmic venous plexus,0.0,,,,,control condition,70107,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood triglyceride amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,female,84 days,10,,CMO:0000360,serum triglyceride level,,,,168.1424,mg/dl,20.9887,66.372,MMO:0000179,automated blood analysis,opthalmic venous plexus,0.0,,,,,control condition,70108,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood glucose amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,84 days,25,,CMO:0000046,blood glucose level,,,,107,mg/dl,2.6,13.0,MMO:0000179,automated blood analysis,opthalmic venous plexus,0.0,,,,,control condition,70111,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood cholesterol amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,male,84 days,15,,CMO:0000363,serum total cholesterol level,,,,111.969,mg/dl,3.6886,14.2857,MMO:0000179,automated blood analysis,opthalmic venous plexus,0.0,,,,,control condition,70103,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",blood cholesterol amount,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,female,84 days,10,,CMO:0000363,serum total cholesterol level,,,,108.108,mg/dl,1.3431,4.2471,MMO:0000179,automated blood analysis,opthalmic venous plexus,0.0,,,,,control condition,70104,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",arterial blood pressure trait,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,98 days to 84 days,25,,CMO:0000004,systolic blood pressure,,,serial mean,122,mmHg,2.8,14.0,MMO:0000054,tail cuff volume pressure recording,tail,0.0,"average of 3 measurements, on 3 different days",,,,control condition,70109,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",lymphocyte quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0000031,blood lymphocyte count,,,,1.995,x 1000 cells/ul,0.1678,0.628,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,75597,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",leukocyte quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0000027,white blood cell count,,,,2.829,x 1000 cells/ul,0.2325,0.87,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,75606,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",body mass,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,female,84 days,10,,CMO:0000012,body weight,,,,206,g,9.4868,30.0,MMO:0000016,body weighing method,,0.0,,,,,control condition,70098,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",body mass,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,male,84 days,15,,CMO:0000012,body weight,,,,324,g,6.455,25.0,MMO:0000016,body weighing method,,0.0,,,,,control condition,70097,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",B cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0000372,blood B lymphocyte count to total leukocyte count ratio,,,,37.4,%,2.7528,10.3,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,75600,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0000373,blood T lymphocyte count to total leukocyte count ratio,,,,11.8,%,0.7751,2.9,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,75603,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",glucose metabolism trait,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,male,210 days,17,,CMO:0001114,percentage of study population developing diabetes mellitus during a period of time,,,,41,%,,,MMO:0000150,manually read urine glucose test strip,,0.0,,,,,control condition,70116,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",glucose metabolism trait,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,female,210 days,12,,CMO:0001114,percentage of study population developing diabetes mellitus during a period of time,,,,25,%,,,MMO:0000150,manually read urine glucose test strip,,0.0,,,,,control condition,70117,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",glucose metabolism trait,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,male,210 days,17,,CMO:0001112,age at onset/diagnosis of diabetes mellitus,,,,101,d,5.0932,21.0,MMO:0000150,manually read urine glucose test strip,,0.0,,,,,control condition,70122,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",glucose metabolism trait,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,female,210 days,12,,CMO:0001112,age at onset/diagnosis of diabetes mellitus,,,,103,d,4.9075,17.0,MMO:0000150,manually read urine glucose test strip,,0.0,,,,,control condition,70123,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",CD8-positive T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002355,blood CD8 lymphocyte count to total lymphocyte count ratio,,,,0.6,%,0.0802,0.3,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84630,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",natural killer cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002353,blood natural killer cell count to total lymphocyte count ratio,,,,13.8,%,1.3363,5.0,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84633,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",CD4-positive T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002359,blood CD45RC(low) CD4 T lymphocyte count to total lymphocyte count ratio,,,,65.9,%,1.7639,6.6,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84687,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",lymphocyte quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002357,blood CD25 lymphocyte count to total lymphocyte count ratio,,,,70.5,%,1.363,5.1,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84639,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002356,blood RT6.1 positive cell count to total lymphocyte count ratio,,,,3.4,%,0.6682,2.5,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84636,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",CD4-positive T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002354,blood CD4 lymphocyte count to total lymphocyte count ratio,,,,34.1,%,2.1381,8.0,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84627,control condition 324,"Kloting I, et al., Biochem Biophys Res Commun 2001 May 4;283(2):399-405.",CD4-positive T cell quantity,,RS:0000069,BB.SHR-(Gnal-D18Mit9)/K,both,90 days,14,,CMO:0002358,blood CD45RC(high) CD4 T lymphocyte count to total lymphocyte count ratio,,,,4.8,%,0.4276,1.6,MMO:0000310,fluorescence-activated cell sorting method,opthalmic venous plexus,0.0,,,,,control condition,84684,control condition